MANITOBA

FIRAZYR is covered by Manitoba Pharmacare (Exception Drug Status Program)

Eligibility

For FIRAZYR to be eligible for coverage by Manitoba Pharmacare, prescribers must submit a request under Pharmacare’s Exception Drug Status Program and the request must be approved before the patient fills the prescription. Deductibles may apply. For more information concerning the reimbursement process, contact OnePath®.

Reimbursement Criteria

We are pleased to inform you that FIRAZYR (icatibant acetate) is reimbursed in Manitoba for your hereditary angioedema (HAE) patients who meet the following criteria:

For the treatment of acute attacks of HAE in adults with lab confirmed C1-esterase inhibitor deficiency (type I or type II) if the following conditions are met:

  • Treatment of acute non-laryngeal attacks of at least moderate severity, OR
  • Treatment of acute laryngeal attacks
  • Limited to a single dose for self-administration, AND
  • Prescribed by an allergist with experience in the treatment of HAE, AND
  • Up to 2 doses on hand at any one time

OnePath® Patient Support Program will help navigate insurance coverage and access reimbursement to medication through private and public insurance companies.

Find Out More

Source: Manitoba Pharmacare Drug Formulary. Part 3 Exception Drug Status.
https://www.gov.mb.ca/health/mdbif/docs/edsnotice.pdf